Abbott launches HBsAg Next Assay in India for Hepatitis B detection

Global healthcare leader Abbott has announced the launch of the HBsAg Next Qualitative solution in India to enhance detection of the Hepatitis B virus (HBV).

This assay will help improve patient outcomes while maintaining safe blood supplies. This highly sensitive chemiluminescent microparticle immunoassay (CMIA) assists in the early and enhanced detection of HBV in human serum and plasma (blood) samples and in population screening. A chemiluminescent immunoassay is a variation of the standard enzyme immunoassay, a biochemical technique used in immunology.

For more information, check out the full story on the link below: 

Abbott unveils HBsAg Next Assay in India for Hepatitis B detection